The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the erspc risk calculator for prostate cancer in prescreened men

European Urology

Volumn 66, Issue 6, 2014, Pages 1109-1115

  Vedder, Moniek M ^a   De Bekker Grob, Esther W ^a   Lilja, Hans G ^b,c,d,e   Vickers, Andrew J ^b   Van Leenders, Geert J L H ^a   Steyerberg, Ewout W ^a   Roobol, Monique J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d LUND UNIVERSITY   (Sweden)

^e TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Kallikrein panel (4k panel); Percentage of free to total PSA; Prostate biopsy; Prostate cancer; Prostate cancer antigen 3 (PCA3); Prostate cancer risk calculator; Validation

Indexed keywords

KALLIKREIN; PROSTATE ANTIGEN; PROSTATE CANCER ANTIGEN 3; PROSTATE SPECIFIC ANTIGEN; TUMOR ANTIGEN; TUMOR MARKER; UNCLASSIFIED DRUG; PROSTATE CANCER ANTIGEN 3, HUMAN;

AGED; ARTICLE; CANCER PATIENT; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DIGITAL RECTAL EXAMINATION; HIGH RISK PATIENT; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTIVE VALUE; PROSTATE BIOPSY; PROSTATE CANCER; REFERENCE VALUE; RESCREENING; RISK ASSESSMENT; SERUM; TRANSRECTAL ULTRASONOGRAPHY; TUMOR BIOPSY; AREA UNDER THE CURVE; BIOPSY; BLOOD; DIAGNOSTIC IMAGING; EARLY CANCER DIAGNOSIS; ECHOGRAPHY; MULTIVARIATE ANALYSIS; NETHERLANDS; PATHOLOGY; PROCEDURES; PROSTATE; PROSTATIC NEOPLASMS; RECEIVER OPERATING CHARACTERISTIC; STATISTICAL MODEL;

AGED; ANTIGENS, NEOPLASM; AREA UNDER CURVE; BIOMARKERS, TUMOR; BIOPSY; DIGITAL RECTAL EXAMINATION; EARLY DETECTION OF CANCER; HUMANS; KALLIKREINS; MALE; MODELS, STATISTICAL; MULTIVARIATE ANALYSIS; NETHERLANDS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; ROC CURVE; ULTRASONOGRAPHY;

EID: 84910080750     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2014.08.011     Document Type: Article

References (32)

1. A. Heidenreich, J. Bellmunt, and M. Bolla EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease Eur Urol 59 2011 61 71
2. G. Draisma, R. Boer, S.J. Otto, and I.W. van der Cruijsen Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer J Natl Cancer Inst 95 2003 868 878
3. E.A. Heijnsdijk, A. der Kinderen, E.M. Wever, G. Draisma, M.J. Roobol, and H.J. de Koning Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer Br J Cancer 101 2009 1833 1838
4. E.W. Steyerberg, M.J. Roobol, M.W. Kattan, T.H. van der Kwast, H.J. de Koning, and F.H. Schroder Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram J Urol 177 2007 107 112 discussion 112
5. I.M. Thompson, D.P. Ankerst, and C. Chi Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial J Natl Cancer Inst 98 2006 529 534
6. P.I. Karakiewicz, S. Benayoun, and M.W. Kattan Development and validation of a nomogram predicting the outcome of prostate biopsy based on patient age, digital rectal examination and serum prostate specific antigen J Urol 173 2005 1930 1934
7. M.J. Bussemakers, A. van Bokhoven, and G.W. Verhaegh DD3: a new prostate-specific gene, highly overexpressed in prostate cancer Cancer Res 59 1999 5975 5979
8. D. Hessels, and J.A. Schalken The use of PCA3 in the diagnosis of prostate cancer Nat Rev Urol 6 2009 255 261
9. A.J. Vickers, A.M. Cronin, and G. Aus A panel of kallikrein markers can reduce unnecessary biopsy for prostate cancer: data from the European Randomized Study of Prostate Cancer Screening in Goteborg, Sweden BMC Med 6 2008 19
10. A. Gupta, M.J. Roobol, and C.J. Savage A four-kallikrein panel for the prediction of repeat prostate biopsy: data from the European Randomized Study of Prostate Cancer screening in Rotterdam, Netherlands Br J Cancer 103 2010 708 714
11. F.H. Schroder, L.J. Denis, and M. Roobol The story of the European Randomized Study of Screening for Prostate Cancer BJU Int 92 Suppl 2 2003 1 13
12. F.H. Schroder, J. Hugosson, and M.J. Roobol Screening and prostate-cancer mortality in a randomized European study N Engl J Med 360 2009 1320 1328
13. M.J. Roobol, F.H. Schröder, and P. van Leeuwen Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test Eur Urol 58 2010 475 481
14. M.J. Roobol, H.A. van Vugt, and S. Loeb Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators Eur Urol 61 2012 577 583
15. A. Vickers, A. Cronin, and M. Roobol Reducing unnecessary biopsy during prostate cancer screening using a four-kallikrein panel: an independent replication J Clin Oncol 28 2010 2493 2498
16. M.J. Roobol, X. Zhu, and F.H. Schroder A calculator for prostate cancer risk 4 years after an initially negative screen: findings from ERSPC Rotterdam Eur Urol 63 2013 627 633
17. M.J. Roobol, F.H. Schroder, and R. Kranse ERSPC Rotterdam. A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam) Prostate 66 2006 604 612
18. A.J. Vickers, and E.B. Elkin Decision curve analysis: a novel method for evaluating prediction models Med Decis Making 26 2006 565 574
19. E.W. Steyerberg, A.J. Vickers, and N.R. Cook Assessing the performance of prediction models: a framework for traditional and novel measures Epidemiology 21 2010 128 138
20. A.J. Vickers, A.M. Cronin, E.B. Elkin, and M. Gonen Extensions to decision curve analysis, a novel method for evaluating diagnostic tests, prediction models and molecular markers BMC Med Inform Decis Mak 8 2008 53
21. T. Steuber, A. Vickers, and A. Haese Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy Int J Cancer 120 2007 1499 1504
22. M. Auprich, A. Haese, and J. Walz External validation of urinary PCA3-based nomograms to individually predict prostate biopsy outcome Eur Urol 58 2010 727 732
23. M. Auprich, F.K. Chun, and J.F. Ward Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging Eur Urol 59 2011 96 105
24. M.J. Roobol, F.H. Schröder, and G.L. van Leenders Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥100) Eur Urol 58 2010 893 899
25. S. Carlsson, A. Maschino, and F. Schroder Predictive value of four kallikrein markers for pathologically insignificant compared with aggressive prostate cancer in radical prostatectomy specimens: results from the European Randomized Study of Screening for Prostate Cancer section Rotterdam Eur Urol 64 2013 693 699
26. B. Malavaud, O. Cussenot, and N. Mottet Impact of adoption of a decision algorithm including PCA3 for repeat biopsy on the costs for prostate cancer diagnosis in France J Med Econ 16 2013 358 363
27. M.B. Nichol, J. Wu, J. Huang, D. Denham, S.K. Frencher, and S.J. Jacobsen Cost-effectiveness of Prostate Health Index for prostate cancer detection BJU Int 110 2012 353 362
28. A. Fandella Analysis of costs of transrectal prostate biopsy Urologia 78 2011 288 292
29. A. Haese, A. de la Taille, and H. van Poppel Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur Urol 54 2008 1081 1088
30. M. Gittelman, B. Hertzman, and J. Bailen PCA3 molecular urine test as a predictor of repeat prostate biopsy outcome in men with previous negative biopsies: a prospective multicenter clinical study J Urol 190 2013 64 69
31. E. Vittinghoff, and C.E. McCulloch Relaxing the rule of ten events per variable in logistic and Cox regression Am J Epidemiol 165 2007 710 718
32. F.H. Schröder, R.C. van den Bergh, and T. Wolters Eleven-year outcome of patients with prostate cancers diagnosed during screening after initial negative sextant biopsies Eur Urol 57 2010 256 266